Study finds slight increased risk of sudden vision loss with GLP-1 drugs
Glucagon-like peptide-1 (GLP-1) receptor agonists—widely prescribed for type 2 diabetes and obesity—may carry a small but clinically important safety signal, ...
Glucagon-like peptide-1 (GLP-1) receptor agonists—widely prescribed for type 2 diabetes and obesity—may carry a small but clinically important safety signal, ...
Newly Expanded FDA Approval Spurs Significant Uptake in Medicare Coverage of Wegovy for Cardiovascular Risk Reduction Following a pivotal FDA ...
A recent large-scale cohort study sheds new light on the psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely ...
Obesity treatment has entered a transformative era with the rise of incretin-based therapies (IBTs), notably GLP-1 receptor agonists, which have ...
A groundbreaking cohort study published recently in JAMA Network Open has revealed a promising therapeutic strategy to mitigate the risk ...
Recent advancements in the field of addiction medicine have positioned GLP-1 receptor agonists as a promising therapeutic option for individuals ...
In a groundbreaking advancement at the intersection of endocrinology and neurology, a recent phase 2 randomized trial has unveiled promising ...
A groundbreaking study conducted by researchers at the University of California San Diego has unveiled compelling evidence suggesting that glucagon-like ...
A groundbreaking new study conducted by researchers at Intermountain Health in Salt Lake City has delivered reassuring news for patients ...
Research on diabetes management is evolving rapidly, with new medications emerging to tackle the challenges faced by patients with Type ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine